[Development of therapeutic agents for diabetic neuropathies].
Nakamura
Jiro
J
Division of Metabolic Diseases, Department of Internal Medicine, Nagoya University Graduate School of Medicine.
D000449:Aldehyde Reductase / Q000037:antagonists & inhibitors; D000975:Antioxidants / Q000627:therapeutic use*; D002096:C-Peptide / Q000627:therapeutic use; D003929:Diabetic Neuropathies / Q000209:etiology* / Q000628:therapy*; D015195:Drug Design; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D015316:Genetic Therapy; D017127:Glycation End Products, Advanced; D053823:Hedgehog Proteins; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D008301:Maleimides / Q000627:therapeutic use*; D020932:Nerve Growth Factor / Q000627:therapeutic use; D018384:Oxidative Stress; D011108:Polymers / Q000378:metabolism; D011493:Protein Kinase C / Q000037:antagonists & inhibitors / Q000378:metabolism; D012236:Rhodanine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013830:Thiadiazoles / Q000627:therapeutic use; D013831:Thiamine / Q000031:analogs & derivatives / Q000627:therapeutic use; D013844:Thiazoles / Q000627:therapeutic use; D053778:Thiazolidines; D015534:Trans-Activators / Q000627:therapeutic use; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics
D000975:Antioxidants; D002096:C-Peptide; D004791:Enzyme Inhibitors; D017127:Glycation End Products, Advanced; D053823:Hedgehog Proteins; D007211:Indoles; D008301:Maleimides; C105739:OPB 9195; D011108:Polymers; D013830:Thiadiazoles; D013844:Thiazoles; D053778:Thiazolidines; D015534:Trans-Activators; D042461:Vascular Endothelial Growth Factor A; C024617:polyol; C038131:epalrestat; C099154:ruboxistaurin; D012236:Rhodanine; D020932:Nerve Growth Factor; C406794:alagebrium; D000449:Aldehyde Reductase; D011493:Protein Kinase C; D013831:Thiamine; C013835:benphothiamine